Annual report [Section 13 and 15(d), not S-K Item 405]

License Agreements (Avenue) (Details)

v3.26.1
License Agreements (Avenue) (Details) - Avenue
 1 Months Ended 12 Months Ended
Apr. 24, 2025
USD ($)
Feb. 28, 2023
USD ($)
item
Jul. 31, 2025
USD ($)
May 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
AnnJi License Agreement          
License Agreements          
Upfront fees paid   $ 3,000,000      
Consideration paid   $ 1,200,000      
Number of tranches of shares | item   2      
AnnJi License Agreement | Maximum          
License Agreements          
Reimbursement payable in connection with clinical trial   $ 10,800,000      
Development milestone payable, US   14,500,000      
Development milestone payable, outside US   27,500,000      
Sales milestone payable   165,000,000      
Annual net sales as basis for milestone payments   750,000,000      
AnnJi License Agreement | Minimum          
License Agreements          
Annual net sales as basis for milestone payments   $ 75,000,000      
Termination and Transfer Agreement          
License Agreements          
Period not to compete 48 months        
Share repurchase, amount paid $ 1        
Legal expense reimbursed $ 200,000       $ 200,000
Termination payments receivable       $ 1,600,000 $ 1,600,000
Percentage of withholding tax       20.00%  
Termination paid     $ 800,000 $ 800,000  
Percentage of royalty on future net sales 1.75%        
Percentage to be received on third party licensing revenue 15.00%        
Termination and Transfer Agreement | Maximum          
License Agreements          
Development and regulatory milestone payments receivable $ 5,000,000        
Sales milestone payments receivable 17,000,000        
Maximum amounts to be received on third party licensing revenue 7,500,000        
Termination and Transfer Agreement | Minimum          
License Agreements          
Maximum amounts to be received on third party licensing revenue $ 4,000,000